Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up

Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up

Background: Vaccination remains the primary measure to prevent the spread of the SARS-CoV-2 virus, further necessitating the use of effective licensed vaccines. Methods: From Dec 25, 2020, to July 11, 2021, we conducted a multicenter, randomised, single-blind, placebo-controlled phase 3 efficacy tri...

Full description

Bibliographic Details
Main Authors: Abduraimov, Y. (Author), Assanzhanova, N. (Author), Burashev, Y. (Author), Buzitskaya, Z. (Author), Chervyakova, O. (Author), Davlyatshin, T. (Author), Kassenov, M. (Author), Kerimbayev, A. (Author), Khairullin, B. (Author), Kulmagambetov, I. (Author), Kutumbetov, L. (Author), Myrzakhmetova, B. (Author), Nakhanov, A. (Author), Nurabayev, S. (Author), Nurpeisova, A. (Author), Orynbayev, M. (Author), Sarsenbayeva, G. (Author), Sergeeva, M. (Author), Stukova, M. (Author), Sultankulova, K. (Author), Yershebulov, Z. (Author), Zakarya, K. (Author), Zhugunissov, K. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Clinical trial
COVID-19
Efficacy
Phase 3
Vaccine
Virus
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items